Pharmaceutical

Cell and gene therapy companies must demonstrate strong value proposition for investment          

Investment for companies developing cell and gene therapies (CGTs) was discussed during the GenScript Biotech Global Forum London 2024 conference held on 20 November 2024.

Dec 7, 2024 - 06:00
Cell and gene therapy companies must demonstrate strong value proposition for investment          
Investment for companies developing cell and gene therapies (CGTs) was discussed during the GenScript Biotech Global Forum London 2024 conference held on 20 November 2024.
Read the original article

Tags:

Previous Article

New study finds obesity costs US industry $347bn a year

Next Article

Eli Lilly to invest $3bn in Wisconsin facility expansion

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Forbion raises $1.47bn for two life sciences-focused funds

Forbion raises $1.47bn for two life sciences-focused funds

Apr 20, 2023

STAT+: Why do some blood stem cells go rogue? Study offers clue and possible target

STAT+: Why do some blood stem cells go rogue? Study off...

Apr 17, 2023

STAT+: Fiery MedPAC meeting highlights massive overpayments in Medicare Advantage

STAT+: Fiery MedPAC meeting highlights massive overpaym...

Jan 12, 2024